No Data
No Data
Buy Rating for Quoin Pharmaceuticals: Promising Phase 3 Results for QRX003 in Netherton Syndrome
$QNRX Stock Is up 43% Today. Here's What We See in Our Data.
Quoin Pharmaceuticals Announces Highly Positive 'Whole Body' Clinical Data From Ongoing Pediatric Netherton Syndrome Study
Quoin Pharmaceuticals Launches First Episode of 'NETHERTON NOW' Series
Express News | Quoin Pharmaceuticals Launches First Episode In Its "Living With Netherton" Video Series
Quoin Pharmaceuticals Launches 'NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease With No Approved Treatment or Cure
Unlock the Full List